An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Trial Profile

An Open-Label, Phase 1/2A Dose Escalation Study of Safety and Efficacy of NEO100 in Recurrent Grade IV Glioma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 16 Sep 2017

At a glance

  • Drugs Perillyl alcohol (Primary)
  • Indications CNS cancer; Glioblastoma; Glioma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors NEONC Technologies
  • Most Recent Events

    • 13 May 2016 According to an NEONC Technologies media release, the clinical study consists of two phases; first a dose escalation phase, followed by 25 patients being treated at the highest dose that is well tolerated.
    • 15 Apr 2016 Status changed from not yet recruiting to recruiting.
    • 13 Apr 2016 Planned initiation date changed from 1 Mar 2016 to 1 Apr 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top